Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study

Koršić, Marta; Badovinac, Sonja; Čučević, Branka; Janevski, Zoran

doi:10.1007/s00508-015-0716-8

Cited by 12 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst pleurodesis aims to palliate symptoms rather than extend survival, one retrospective non-randomised study found talc poudrage pleurodesis was associated with longer survival compared with repeated thoracentesis [40]. However, the authors conflated correlation with causality, and ignored potential confounding by indication in the two treatment arms.…”

Section: Other Issues Regarding Talc Pleurodesismentioning

confidence: 99%

ERS/EACTS statement on the management of malignant pleural effusions

et al. 2018

View full text Add to dashboard Cite

Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE management. The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature.Six areas of interest were identified, including the optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE.The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE. There was limited evidence regarding the management of trapped lung or loculated MPE. The LENT score was identified as a validated tool for predicting survival in MPE, with Brims' prognostic score demonstrating utility in mesothelioma prognostication. There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.

show abstract

Section: Other Issues Regarding Talc Pleurodesismentioning

confidence: 99%

ERS/EACTS statement on the management of malignant pleural effusions

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We read with interest the article entitled 'Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer' by Chiang et al 1 We have been particularly interested in the management of pleural effusion in patients with lung cancer, [2][3][4] and we would like to raise four issues arising from the article by Chiang et al…”

Section: To the Editorsmentioning

confidence: 99%

Early pleural effusion control in patients with lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interestingly, pleurodesis may have an antitumor effect and alter the natural history of cancers by inducing inflammation and increasing the survival rates among the mesothelioma patients with MPE. 23,75…”

Section: Malignant Pleural Effusionsmentioning

confidence: 99%

Pleurodesis

Lamb

Thakkar

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Symptomatic pleural disease, specifically malignant pleural effusion, refractory benign pleural effusion, and pneumothoraces are common diseases that often require therapeutic interventions. The spectrum of management strategies often includes selection of a chemical pleurodesis agent administered in combination with an indwelling pleural catheter or chest tube.Additionally, there is a role for minimally invasive techniques which include medical thoracoscopy or more advanced video-assisted thoracoscopic approaches. Ongoing clinical trials continue to evolve best practices regarding the optimal sclerosant agents and procedural approaches in the management of these diseases.

show abstract

Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study

Cited by 12 publications

References 28 publications

ERS/EACTS statement on the management of malignant pleural effusions

ERS/EACTS statement on the management of malignant pleural effusions

Early pleural effusion control in patients with lung cancer

Pleurodesis

Contact Info

Product

Resources

About